What is the role of aromatase inhibitors (AIs) in the treatment of ovarian cancer?

Updated: Aug 10, 2020
  • Author: Andrew E Green, MD; Chief Editor: Yukio Sonoda, MD  more...
  • Print

Several reports have documented the use of the aromatase inhibitor anastrozole, which inhibits the conversion of androstenedione to estrone, in the management of patients who previously received surgery and chemotherapy.  [115]  Patients with recurrent disease have demonstrated normalization of their serum inhibin, decrease in tumor size, and an increase in disease-free survival. Several authors have recommended aromatase inhibitors as a treatment strategy for recurrent and refractory disease. Currently, however, the number of cases is too small to draw any conclusions, and the use of aromatase inhibitors should be considered strictly experimental.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!